There were 823 press releases posted in the last 24 hours and 183,720 in the last 365 days.

Global Chronic Aspergillosis Treatment Market to Surpass US$ 4,056.4 Million by 2028, Says Coherent Market Insights (CMI)

/EIN News/ -- SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global chronic aspergillosis treatment market is estimated to be valued at US$ 2,916.3 million in 2021 and is expected to exhibit a CAGR of 4.8% during the forecast period (2021-2028).

Key Trends and Analysis of the Global Chronic Aspergillosis Treatment Market:

Increasing prevalence of aspergillosis is expected to drive the growth of global chronic aspergillosis treatment market over the forecast period. For instance, according to a study published in Journal of Fungi 2016, Chronic Pulmonary Aspergillosis (CPA) is estimated to affect nearly three million people globally making it a major health problem which results in mortality and morbidity.

Key Market Takeaways:

The global chronic aspergillosis treatment market is expected to exhibit a CAGR of 4.8% during the forecast period due to key players operating in the market are focusing on U.S. Food and Drug Administration (FDA) approval for the treatment of chronic aspergillosis is expected to drive the global chronic aspergillosis treatment market over the forecast period. For instance, in June 2020, F2G Ltd. announced that the U.S. Food and Drug Administration (FDA) had granted Qualified Infectious Disease Product (QIDP) designation to its lead first-in-class candidate, olorofim (formerly F901318), for the indications of invasive aspergillosis and others.

Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4611

Among drug class, anti-fungal drugs segment is estimated to hold a dominant position in the global chronic aspergillosis treatment market over forecast period. Moreover, key companies in the market are focusing on growth strategies such as product launches which is expected to drive segment growth over forecast period. For instance, in January 2019, Mayne Pharma Group Limited announced the launch of TOLSURA (SUBA-itraconazole) 65mg capsule in the U.S. TOLSURA is a new formulation of itraconazole indicated for the treatment of systemic fungal infections including aspergillosis, blastomycosis, and histoplasmosis.

On the basis of disease type, severe asthma with fungal sensitization [SAFS] segment is estimated to hold a dominant position in the global chronic aspergillosis treatment market over forecast period. Moreover, rising incidence of asthma across the world is expected to drive the segment growth over the forecast period. For instance, according to the Life Leading International Fungal Education it is estimated that severe asthma affects 5-20% of those with asthma worldwide, of these, 35-50% have SAFS, depending on how extensively they are tested. Six million of people with SAFS is a conservative estimate by the same source.

Competitive Landscape:

Key players operating in the global allergic conjunctivitis market include Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4611

Market Segmentation:

  • Global Chronic Aspergillosis Treatment Market, By Drug Class :
    • Corticosteroids
    • Anti-fungal Drugs
  • Global Chronic Aspergillosis Treatment Market, By Disease Type :
    • Simple Aspergilloma
    • Chronic Cavitary Pulmonary Aspergillosis
    • Chronic Fibrosing Pulmonary Aspergillosis
    • Subacute Invasive Aspergillosis
    • Allergic Bronchopulmonary Aspergillosis [ABPA]
    • Severe Asthma With Fungal Sensitization [SAFS]
  • Global Chronic Aspergillosis Treatment Market, By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies and Drug Store
    • E-commerce
  • Global Chronic Aspergillosis Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

Aspergillosis Treatment Market, by Drug Class (Corticosteroids and Anti-fungal), by Disease Type (Invasive Aspergillosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Allergic Aspergillus Sinusitis, Aspergilloma, and Cutaneous Aspergillosis) and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Acute Invasive Aspergillosis Treatment Market, by Drug Type (Antifungals (Voriconazole, Capsofungin, Itraconazole, Isavuconazole, Amphotericin B, and Others) Corticosteroids (Prednisolone, Prednisone, and Methylprednisolone)), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Follow Us: LinkedInTwitter


Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights

Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

Primary Logo